The Phantom of Metformin-Induced Lactic Acidosis in End-Stage Renal Disease Patients: Time to Reconsider with Peritoneal Dialysis Treatment

Abstract

Objective

Metformin continues to be the safest and most widely used antidiabetic drug. In spite of its well-known benefits; metformin use in end-stage renal disease (ESRD) patients is still restricted. Little has been reported about the effect of peritoneal dialysis (PD) on metformin clearance and the phantom of lactic acidosis deprives ESRD patients from metformin therapeutic advantages. Peritoneal dialysis is probably a safeguard against lactic acidosis, and it is likely that using this drug would be feasible in this group of patients.

Material and methods

The study was conducted on 83 PD patients with type 2 diabetes mellitus. All patients were on automated PD (APD). Metformin was administered in a dose of 500 - 1,000 mg daily. Patients were monitored for glycemic control. Plasma lactic acid and plasma metformin levels were monitored on a scheduled basis. Peritoneal fluid metformin levels were measured. In addition, the relation between plasma metformin and plasma lactate was studied.

Results

Mean fasting blood sugar (FBS) was 10.9 ± 0.5 and 7.8 ± 0.7, and mean hemoglobin A1-C (HgA1C) was 8.2 ± 0.8 and 6.4 ± 1.1 at the beginning and end of the study, respectively (p < 0.001). The mean body mass index (BMI) was 29.1 ± 4.1 and 27.3 ± 4.5 at the beginning and at the end of the study, respectively (p < 0.001). The overall mean plasma lactate level across all blood samples was 1.44 ± 0.6. Plasma levels between 2 and 3 mmol/L were found in 11.8% and levels of 3 - 3.6 mmol/L in 2.4% plasma samples. Hyperlactemia (level > 2 and < 5 mmol/L) was not associated with overt acidemia. None of our patients had lactic acidosis (levels > 5 mmol/L). Age ≥ 60 was a predictor for hyperlactemia. No relationship was found between plasma metformin and lactate levels.

Conclusion

Metformin may be used with caution in a particular group of ESRD patients who are on APD. Metformin allows better diabetic control with significant reduction of BMI. Information on the relationship between metformin and plasma lactate levels is lacking. Peritoneal dialysis appears to be a safeguard against the development of lactic acidosis in this group of patients.

Keywords

Type 2 diabetes mellitus metformin lactic acidosis ESRD peritoneal dialysis Hemoglobin A1-C BMI PET

Get full access to this article

View all access options for this article.

References

Bailey

C.J.

, Turner

R.C.

Metformin.

N Engl J Med 1996; 334: 574–9.

Lamanna

, Monami

, Marchionni

, Mannucci

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.

Diabetes Obes Metab 2011; 13: 221–8.

Basevi

, Di Mario

, Morciano

, Nonino

, Magrini

Comment on: American Diabetes Association. Standards of medical care in diabetes—2011.

Diabetes Care 2011; 34(Suppl 1): S11–61.

Stades

A.M.E.

, Heikens

J.T.

, Erkelens

D.W.

, Holleman

, Hoekstra

J.B.

Metformin and lactic acidosis: cause or coincidence? A review of case reports.

J Int Med 2004; 255: 179–87.

Pepper

G.M.

, Schwartz

Lactic acidosis associated with glucophage use in a man with normal renal and hepatic function (Letter).

Diabetes Care 1997; 20: 232–3.

Al-Hwiesh

A.K.

, Abdul-Rahman

I.S.

, Nasr El-Deen

M.A.

, Larbi

, Divino-Filho

J.C.

, Al-Mohanna

F.A.

Metformin in peritoneal dialysis: a pilot experience.

Perit Dial Int 2014; 34(4): 368–75.

Misbin

R.I.

The phantom of lactic acidosis due to metformin in patients with diabetes.

Diabetes Care 2004; 27: 1791–3.

Salpeter

S.R.

, Greyber

, Pasternak

G.A.

, Salpeter

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Cochrane Database Syst Rev 2002; (2): CD002967.

Lalau

J.D.

, Race

J.M.

Lactic acidosis and metformin therapy: searching for a link with metformin in reports of “metformin-associated lactic acidosis.”

Diabetes Obes Metab 2001; 3: 195–201.

10.

Heaf

J.G.

, van Biesen

Metformin and chronic renal impairment: a story of choices and ugly ducklings.

Clin Diabetes 2011; 20: 97–101.

11.

Lipska

K.J.

, Bailey

C.J.

, Inzucchi

S.E.

Use of metformin in the setting of mild-to-moderate renal insufficiency.

Diabetes Care 2011; 34: 1431–7.

12.

Nye

H.J.

, Herrington

W.G.

Metformin: the safest hypoglycemic agent in chronic kidney disease?

Nephron Clin Pract 2011; 118: c380–3.

13.

Holman

R.R.

Type 2 diabetes mellitus in 2012: optimal management of T2DM remains elusive.

Nat Rev Endocrinol 2013; 9: 67–8.

14.

Ekstrom

, Schioler

, Svensson

A.M.

, Eeq-Olofsson

, Miao Jonasson

, Zethelius

Effectiveness and safety of metformin in 51,675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.

Br Med J Open 2012; 2(4): e001076.

15.

Solini

, Penno

, Bonora

, Fondelli

, Orsi

, Trevison

Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the renal insufficiency and cardiovascular events Italian multicenter study.

J Am Geriatr Soc 2013; 61: 1253–61.

16.

Roussel

, Travert

, Pasquet

, Wilson

P.W.

, Smith

S.C.

Jr. , Goto

Metformin use and mortality among patients with diabetes and atherothrombosis.

Arch Intern Med 2010; 170: 1892–9.

17.

Twardowski

Z.I.

, Nolph

K.D.

, Khanna

Peritoneal equilibrium test.

Perit Dial Bull 1987; 7: 138–47.

18.

Scheen

A.J.

Clinical pharmacokinetics of metformin.

Clin Pharmacokinet 1996; 30: 359–71.

19.

Holman

R.R.

, Paul

S.K.

, Bethel

M.A.

, Matthews

D.R.

, Neil

H.A.

10-year follow-up of intensive glucose control in type 2 diabetes.

N Engl J Med 2008; 359: 1577–89.

20.

Selvin

, Bolen

, Yeh

H-C

, Wiley

, Wilson

L.M.

, Marinopoulos

S.S.

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

Arch Intern Med 2008; 168: 2070–80.

21.

Lamanna

, Monami

, Marchionni

, Mannucci

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.

Diabetes Obes Metab 2011; 13: 221–8.

22.

Eurich

D.T.

, Majundar

S.R.

, McAlister

F.A.

Improved clinical outcomes associated with metformin in patients with diabetes and heart Failure.

Diabetes Care 2005; 28: 2345–51.

23.

Garvey

W.T.

, Ryan

D.H.

, Look

, Gadde

K.M.

, Allison

D.B.

, Peterson

C.A.

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.

Am J Clin Nutr 2012; 95: 297–308.

24.

Fox

C.S.

, Golden

S.H.

, Anderson

, Bray

G.A.

, Burke

L.E.

, de Boer

I.H.

Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association.

Diabetes Care 2015; 38: 1777–803.

25.

Bray

G.A.

, Ryan

D.H.

Medical therapy for the patient with obesity.

Circulation 2012; 125: 1695–703.

26.

UK Prospective Diabetes Study Group.

Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).

Lancet 1998; 352: 854–65.

27.

Yamanouchi

, Sakai

, Igarashi

, Ichiyanaqi

, Watanabi

, Kawasaki

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes.

Diabet Med 2005; 22: 980–5.

28.

Schernthaner

, Matthews

D.R.

, Charbonnel

, Hanefeld

, Brunetti

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

J Clin Endocrinol Metab 2004; 89: 6068–76.

29.

DeFronzo

R.A.

, Goodman

A.M.

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

N Engl J Med 1995; 333: 541–9.

30.

Hoffmann

, Spengler

Efficacy of 24-week monotherapy with acarabose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.

Am J Med 1997; 103: 483–90.

31.

Del Prato

, Erkelens

D.W.

, Leutenegger

Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients.

Acta Diabetol 2003; 40: 20–7.

32.

Virtanen

K.A.

, Hallsten

, Parkkola

, Janatuinen

, Lonngvist

, Vilianen

Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.

Diabetes 2003; 52: 283–90.

33.

Aviles-Santa

, Sinding

, Raskin

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

Ann Intern Med 1999; 131: 182–8.

34.

Graham

G.G.

, Punt

, Arora

, Day

R.O.

, Dooque

M.P.

, Doung

J.K.

Clinical pharmacokinetics of metformin.

Clin Pharmacokinet 2011; 50: 81–98.

35.

Bodmer

, Meier

, Krahenbuhl

, Jick

S.S.

, Meier

C.R.

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

Diabetes Care 2008; 31: 2086–91.

36.

Mani

M.K.

Nephrologists sans frontières: preventing chronic kidney disease on a shoestring.

Kidney Int 2006; 70: 821–3.

37.

Salpeter

S.R.

, Greyber

, Pasternak

G.A.

, Salpeter

E.E.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Cochrane Database Syst Rev 2010; 4: CD002967.

38.

Bando

, Ochiai

, Kunimatsu

, Deguchi

, Kimura

, Funabashi

Comparison of potential risks of lactic acidosis induction by biguanides in rats.

Regul Toxicol Pharmacol 2010; 58: 155–60.

39.

Holstein

, Stumvoll

Contraindications can damage your health—is metformin a case in point?

Diabetologia 2005; 48: 2454–9.

40.

National Institute for Health and Care Excellence. Type 2 diabetes: the management of type 2 diabetes: NICE Clinical Guideline 2009; 87.

41.

Salpeter

S.R.

, Greyber

, Pastemal

G.A.

, Salpeter

E.E.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.

Arch Intern Med 2003; 163: 2594–602.

42.

Kruse

J.A.

Review: metformin does not increase the risk for lactic acidosis or increase lactate levels in type 2 diabetes.

ACP Journal Club 2004; 141(1): 7.

43.

Sheppard

J.M.

, Lawrence

J.R.

, Oon

R.C.

, Thomas

D.W.

, Row

P.G.

, Wise

P.H.

Lactic acidosis: recovery associated with use of peritoneal dialysis.

Aust N Z JM 1972; 2: 389–92.

44.

Hayat

J.C.

The treatment of lactic acidosis in diabetic patients by peritoneal dialysis using sodium acetate: a report of two cases.

Diabetologia 1974; 10(5): 485–7.

45.

Assan

, Heuclin

, Ganeval

, Bismuth

, George

, Girard

J.R.

Metformin induced lactic acidosis in the presence of acute renal failure.

Diabetologia 1977; 13: 211–7.

46.

Vazini

N.D.

, Ness

, Wellikson

Bicarbonate-buffered peritoneal dialysis: an effective adjunct in the treatment of lactic acidosis.

Am J Med 1979; 67: 392–6.

47.

Schmidt

, Horn

, Richards

, Stamatakis

Survival after metformin-associated lactic acidosis in peritoneal dialysis-dependent renal failure.

Am J Med 1997; 102: 486–8.

48.

Warner

, Vazini

N.D.

Treatment of lactic acidosis.

South Med J 1981; 74: 841–7.

49.

Lalau

J.D.

, Race

J.M.

Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations.

Drug Saf 1999; 20: 377–84.

50.

Duong

J.K.

, Roberts

D.M.

, Furlong

T.J.

, Kumar

S.S.

, Greenfield

J.R.

, Kirkpatrick

C.M.

Metformin therapy in patients with chronic kidney disease.

Diab Obes Metab 2012; 14: 963–5.

51.

Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR < 45 mL/min). Nephrol Dial Transplant 2015; 30(Suppl 2):ii1–142.